BFRI Form 4: Luebbert Receives 125k RSUs, $1 Options; 137.5k Shares Settled
Rhea-AI Filing Summary
Hermann Luebbert, CEO & Chairman and director of Biofrontera Inc. (BFRI), reported equity awards and option grants during 2024–2025. The Form 4 shows a 07/22/2025 grant of 125,000 restricted stock units (RSUs) and a contemporaneous employee stock option to buy 125,000 shares at $1.00 (exercise through 07/22/2035). On 09/10/2025 a transaction coded "M" reports acquisition of 137,500 shares (via conversion or settlement of RSUs). The RSUs convert one-for-one into common stock and were received for no consideration; some RSUs vest in two equal yearly installments beginning July 22, 2026, and other RSUs granted July 12, 2024 vest beginning July 12, 2025. Vested RSUs may be settled in shares, cash, or a combination within 60 days of vesting. The reporting was signed by an attorney-in-fact on 09/16/2025.
Positive
- Alignment of interests: CEO & Chairman received time‑based RSUs and long‑dated options, linking compensation to future share performance
- Retention focus: Vesting schedules (annual and semiannual) support management retention over multiple years
- Transparent reporting: Transactions documented on Form 4 with signing by attorney‑in‑fact
Negative
- Potential dilution: Grants total at least 250,000 equity awards plus 137,500 shares settled, which may increase share count if settled in stock
- Settlement flexibility: Company may settle vested RSUs in cash or shares, creating earnings or cash flow variability when settled
Insights
TL;DR: Executive received time‑based equity and options, aligning incentives but increasing potential dilution.
The filings show typical executive compensation mechanics: time‑based restricted stock units and a long‑dated option with a $1.00 exercise price, both granted to the CEO & Chairman. Vesting schedules are multi‑year and settlement may be in stock or cash, which preserves flexibility for the company but can create future share issuance. Reporting is timely and signed via attorney‑in‑fact.
TL;DR: Sizeable equity grant (125k RSUs + 125k options) and 137.5k RSU settlement reported; standard vesting cadence observed.
The aggregate awards consist of two RSU tranches and a stock option tranche, each vesting over one to two years or in semiannual installments. The option expires in 2035, indicating long‑term retention goals. The awards were issued for no consideration and include discretionary settlement terms. These are standard instruments to retain and incentivize senior management.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 137,500 | $0.00 | -- |
| Exercise | Common Stock | 137,500 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 125,000 | $0.00 | -- |
| Grant/Award | Employee stock option (right to buy) | 125,000 | $0.00 | -- |
Footnotes (1)
- Restricted stock units convert into common stock on a one-for-one basis. Each restricted stock unit represents a contingent right to receive one share of BFRI common stock. The reporting person received the restricted stock units as an award for no consideration. The restricted stock units vest in two equal yearly installments for the first two years following the grant date, beginning on July 22, 2026. Each vested restricted stock unit will be settled, at the Company's discretion, in shares, cash or a combination of shares and cash within 60 days of the vesting date. The option vests in two equal semi-annual installments beginning on January 22, 2026. On July 12, 2024 the reporting person was granted 275,000 restricted stock units, vesting in two equal annual installments beginning on July 12, 2025. Each vested restricted stock unit will be settled, at the Company's discretion, in shares, cash or a combination of shares and cash within 60 days of the vesting date. Restricted stock units with different terms are not included. Options with different terms are not included.
